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Abstract
Background: Few studies, if any, have examined cardiovascular outcomes in patients with diabetes and gout. Both
diabetes and gout are risk factors for cardiovascular disease. The objective of this study was to examine the effect
of allopurinol on the risk of incident acute cardiovascular events in patients with gout and diabetes.
Methods: We used the 2007–2010 Multi-Payer Claims Database (MPCD) that linked health plan data from national
commercial and governmental insurances, representing beneficiaries with United Healthcare, Medicare, or Medicaid
coverage. In patients with gout and diabetes, we assessed the current allopurinol use, defined as a new filled
prescription for allopurinol, as the main predictor of interest. Our outcome of interest was the occurrence of the
first Incident hospitalized myocardial infarction (MI) or stroke (composite acute cardiovascular event), after which
observations were censored. We employed multivariable-adjusted Cox proportional hazards models that simultaneously
adjusted for patient demographics, cardiovascular risk factors and other medical comorbidities. We calculated hazard
ratios [HR] (95% confidence intervals [CI]) for incident composite (MI or stroke) acute cardiovascular events. We
performed sensitivity analyses that additionally adjusted for the presence of immune diseases and colchicine use, as
potential confounders.
Results: There were 2,053,185 person days (5621.3 person years) of current allopurinol use and 1,671,583 person
days (4576.5 person years) of prior allopurinol use. There were 158 incident MIs or strokes in current and 151 in prior
allopurinol users, respectively. Compared to previous allopurinol users, current allopurinol users had significantly lower
adjusted hazard of incident acute cardiovascular events (incident stroke or MI), with an HR of 0.67 (95% CI, 0.
53, 0.84). Sensitivity analyses, additionally adjusted for immune diseases or colchicine use, confirmed this
association.
Conclusions: Current allopurinol use protected against the occurrence of acute cardiovascular events in patients with
gout and diabetes. The underlying mechanisms for this potential cardio-protective effect of allopurinol need further
exploration.
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Background
Chronic inflammatory conditions, such as rheumatoid arth-
ritis and gout, are associated with significant increase in
cardiovascular morbidity and mortality. Several studies have
reported a higher risk of cardiovascular disease in patients
with gout [1–3]. The evidence supporting the association of
hyperuricemia with increased cardiovascular risk [1, 4–7]
indicates that this may be at least one potential mechanism
for this increased cardiovascular risk in patients with gout.
Allopurinol, a purine analog, acts as a competitive sub-
strate for xanthine oxidase, an enzyme that converts
hypoxanthine to xanthine and xanthine into uric acid.
Thus, it reduces the level of serum urate and acts as a
urate-lowering therapy (ULT). Xanthine oxidase gener-
ates superoxide anions and other oxidative free radicals
that are associated with oxidative stress [8]. Allopurinol
reduces uric acid production and oxidative stress, pro-
cesses that have been hypothesized to be associated with
endothelial dysfunction, inflammation and progression of
atherosclerosis [9]. Thus, allopurinol might have beneficial
effects on cardiac physiology [10, 11].
Recent studies have debated whether allopurinol has a
true cardio-protective effect, i.e., does it reduce the risk
of outcomes such as myocardial infarction (MI)? A case-
control study with a prevalent user design using the
French pharmacoepidemiology database found that allo-
purinol use did not significantly reduce the risk of non-
fatal MI, odds ratio (OR) was 0.80 (95% CI, 0.59, 1.09)
[12]. In contrast, in a nested case-control study using
Spanish primary care database, current allopurinol use
and not past use, was associated with reduction in non-
fatal MI with odds ratios of 0.52 (95% CI, 0.33 to 0.83)
and 0.99 (95% CI, 0.61, 1.61), respectively [13]. Yet
another study of gout patients using Scottish database
reported that compared to non-use, allopurinol use was
associated with higher (not lower) adjusted hazards of
cardiovascular hospitalization (including coronary artery
disease (CAD), hypertensive heart disease, heart failure,
stroke, other cardiovascular diseases) of 1.25 (95% CI,
1.10, 1.41) [14]. These three studies differed in the main
outcome assessed (MI vs. non-fatal MI vs. cardiovascular
hospitalization including heart failure) and the country
setting (France vs. Spain vs. Scotland), which could have
explain the differences in the results between these
three studies.
Key limitations of the previous studies included the
use of a prevalent- user design [12, 14], the potential
lack of adequate statistical power [12, 13], a short
follow-up [13], potential survival bias since non-fatal MI
cases were included [12–14], and the non-exclusion of
patients with previous MI [14]. A prevalent-user design
(used in 2 of the 3 studies) is likely more biased than a
new-user design, due to the potential inclusion of factors
on the causal pathway and the lack of an ability to
capture early events (especially harmful effects) after
starting a medication. Incident user design, in which
medication exposure time begins with a new start of a
medication, allows for more valid treatment comparisons
compared to mixing ongoing users with new users in
the same analysis [15]. Thus, based on the current
knowledge, it is unclear whether allopurinol treatment is
independently associated with better cardiac outcomes.
Gout is commonly associated with several comorbidi-
ties, such as hypertension, diabetes etc. One-third of
gout patients have diabetes [16]. Diabetes, as a major
cardiovascular disease risk factor, affects 26 million
Americans, is among the top 10 causes of death in the
U.S., and cost $245 billion in direct and indirect costs in
2012 [17]. Despite the common occurence of both con-
ditions and associated morbidity, studies of cardiovascu-
lar outcomes in patients with gout and diabetes are
lacking.
We were interested in investigating cardiovascular (CV)
events in patients with gout and concomitant diabetes,
since this group of patients is at high risk of CV events,
given that diabetes is an established CV risk factor and hy-
peruricemia (the key underlying abnormality in gout) has
been implicated as a CV risk factor [1, 4–7]. Therefore
our study objectives were to assess whether in patients
with gout with diabetes, allopurinol therapy was associ-
ated with cardiovascular benefit as demonstrated by a
lower incidence of acute cardiovascular events (myocar-
dial infarction [MI] or stroke).
Methods
Study methods and results are reported as recommended
by the Strengthening of Reporting in Observational stud-
ies in Epidemiology (STROBE) statement [18].
Study cohort and participants
The Institutional Review Board at the University of
Alabama at Birmingham (UAB) approved the study. We
conducted a retrospective cohort study using the Multi-
Payer Claims Database (MPCD) that linked health plan
data from national commercial and governmental insur-
ances, representing beneficiaries with United Healthcare,
Medicare, or Medicaid coverage during 2007–2010. MPCD
data contain patients’ demographic and insurance coverage
information from enrollment files, claims for inpatient and
outpatient services, and prescription medications.
For this analysis, we examined patients who had a
diagnosis of both gout and diabetes. Gout was defined as
the occurrence of an inpatient admission or 2 outpatient
visits with a physician encounter at least 7 days apart
and the presence of International Classification of Dis-
eases, ninth revision, clinical modification [ICD-9-CM]
codes 274.xx for gout, shown to have a positive predict-
ive value >90% [19]. Diabetes was ascertained by the
Singh et al. BMC Cardiovascular Disorders  (2017) 17:76 Page 2 of 9
presence of two ICD-9-CM codes of 250.xx associated
with physician encounter visits at least 7 days apart but
≤365 days and the use of a diabetes-specific medication
[20], also a validated definition with high positive pre-
dictive value >90% [21–23]. The person was diabetes-
eligible and gout-eligible “completely” the day he/she
satisfied both diseases’ eligibility criteria. The index date
(follow up start) of the study cohort was defined as the
day when the criteria for both disease eligibility and the
365 days of continuous coverage were satisfied. The
baseline period was defined as 365 days before the start
of follow up for each eligible participant episode. An in-
dividual was allowed to have more than 1 episode satis-
fying the 365 days of continuous coverage and at least
1 day for follow up, a standard methodology to
maximize use of all data in the incident user design.
Study outcome
The study outcome of interest was incident acute car-
diovascular event, a composite of incident hospitalized
MI or incident hospitalized stroke, in patients with gout
and diabetes. We excluded patients with MI, stroke or
coronary artery disease (CAD) in the baseline 365-day
period for these analyses, using diagnoses for incident or
prevalent cardiovascular disease (410, 412, 430–438,
428, 429.2x) (Additional file 1), in order to analyze the
first incident MI and the first incident stroke.
Incident MI and incident stroke were defined as in-
patient hospitalization with respective ICD-9-CM codes
for MI or stroke with at least 1-day hospital stay, unless
death occurred (Additional file 1). This approach is accur-
ate for case identification with high positive predictive
value >90% for these diagnoses and other cardiovascular
risk factors [23–25].
We censored observation if there was an outpatient
diagnosis of 410.x1 or an inpatient or outpatient diagno-
sis of 410 other than 410.x1 and 412 in the MI analyses
but allowed for a 2-day “grace period” in which MI hos-
pitalizations were sought. For example, someone with an
outpatient diagnosis of MI who was hospitalized for it
within 24 h with hospital length of stay >1-day would
have met the MI definition. For stroke analyses, we cen-
sored patients with grace period of 2-days after the oc-
currence of an outpatient diagnosis of stroke (430.xx,
431.xx, 433.x1, 436.xx, 434.xx except 434.x0) or an in-
patient or outpatient diagnosis of 430–438 other than
that of stroke ICD-9-codes (listed above). This approach
was used due to uncertainties about the clinical rele-
vance of an outpatient diagnosis of MI or stroke and to
exclude prevalent cases of MI or stroke.
Exposure of interest
The study exposure of interest was the new use of allo-
purinol, defined based on a filled prescription for
allopurinol, with no prior filled prescription of allopur-
inol for previous 183 days. We considered exposure days
of medications from 2007 to 2010 allowing up to 30 days
of stock to be carried over (if the medication was refilled
slightly early). We allowed the days of supply of allopur-
inol to be a maximum of 120 days only. A new medica-
tion episode started if a patient had complete coverage
but no filled prescription of allopurinol in previous
183 days. For the main analysis that used a new user de-
sign, we defined various time-varying allopurinol use
categories for each person-day of follow-up as either
current use (present day covered by allopurinol) or prior
use (present day not covered by allopurinol, but prior
period with allopurinol exposure) based on medication
episodes. Each patient could contribute person-time to
each of these groups, as per standard methodology in an
incident user design, to allow maximal use of data.
Covariates and confounders
Study covariates measured in the baseline period were age,
gender and race/ethnicity. We categorized age in 5-year age
group categories and race/ethnicity into Asian, Hispanic,
Black, White, other and missing. Cardiovascular risk factors
other than diabetes (hypertension, hyperlipidemia), and
other medical comorbidities, including chronic obstructive
pulmonary disease (COPD) and renal failure were assessed
based on the presence of respective ICD-9-CM codes dur-
ing the study period prior to occurrence of outcome, as
time-varying variables (Additional file 1). Comorbidities
were categorized as present or absent.
Statistical analyses
We calculated summary statistics as proportion or mean
(standard deviation). Unadjusted comparisons were per-
formed using chi-square or t-tests, as appropriate. Crude
incidence rates for MI and stroke were calculated for
current and prior allopurinol users. We used the new
user design as our main analysis to assess the association
of allopurinol use with outcomes of interest [15].
We performed unadjusted and age-adjusted Cox regres-
sion analyses to obtain hazards of the composite acute
cardiovascular event (incident MI or incident stroke) with
allopurinol use. Multivariable-adjusted Cox regression
analyses were performed next to account for demograph-
ics, cardiovascular risk factors (hypertension, hyperlipid-
emia), and comorbidities (COPD, renal failure). Hazard
ratios for incident acute cardiovascular event were calcu-
lated, based on allopurinol use, current, vs. prior (refer-
ent). We performed statistical analyses using SAS version
9.2. A p-value <0.05 was considered significant.
We performed several sensitivity analyses to test the
robustness of findings by: (1) additionally adjusting for
autoimmune diseases, a potential risk factor for MI/
stroke due to associated chronic inflammation; (2)
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additionally adjusting for the use of colchicine, a com-
monly used anti-inflammatory drug for gout that might
have a cardio-protective effect [26]; or (3) using a preva-
lent user design, where we defined each day of follow-up
as current, prior or never allopurinol use by adding
never allopurinol users, defined as no allopurinol use
(referent) from 2007 till the end of follow up.
Results
Patient demographic and clinical characteristics
We observed 2,053,185 person days of current allopur-
inol use and 1,671,583 person days of prior allopurinol
use. Age distribution across groups was similar; 70.7% of
current and 61.5% of prior allopurinol users were White
(Table 1). Comorbidities were common in both groups:
Hypertension, 85% each; hypercholesterolemia, 78–81%;
and renal disease, 25–28% (Table 1).
Association of allopurinol use with incident MI or
incident stroke
There were 158 and 151 incident acute cardiovascular
events (MIs or strokes) in current and prior allopurinol
users, respectively (Table 2). The crude rate of incident
acute cardiovascular events (MI or stroke) in current
and prior allopurinol users were 2.81 and 3.30 per 100
person-years, respectively. Association of allopurinol use
with incident acute cardiovascular events (MI or stroke)
in unadjusted and age-adjusted analyses including other
significant correlates is shown in Table 3.
In multivariable-adjusted models that accounted for
demographics and cardiovascular risk factors, compared
to prior users, current allopurinol users had significantly
lower hazard of incident stroke or MI, HR was 0.67
(95% CI, 0.53, 0.84) (Table 4). Other significant risk fac-
tors were older age and renal disease (Table 4).
Sensitivity analyses: adjustment for colchicine or immune
disease and by prevalent use
Sensitivity analyses adjusting for colchicine revealed es-
sentially the same results for current allopurinol use (yes/
no) as in the main analyses above (Table 5). Colchicine
was not significantly associated with the risk of incident
MI or stroke, 0.80 (95% CI, 0.55, 1.18) (Table 5). Sensitiv-
ity analyses, additionally adjusted for immune disease con-
firmed the findings from the main analyses (Table 5); the
presence of immune disease was not significantly associ-
ated, 1.04 (95% CI, 0.78, 1.37).
In multivariable adjusted analyses that used a preva-
lent user design analysis (not as robust as incident user
design), we found that current allopurinol use was asso-
ciated with similar hazard reduction of incident MI or
stroke (as in the main analyses) when compared to: (1)
prior allopurinol use, 0.84 (95% CI, 0.72, 0.98); and (2)
never use, 0.86 (95% CI, 0.75, 0.99) (Additional file 2).
Table 1 Characteristics of allopurinol users
All combined (%) Allopurinol use (%)
Current‡ Previous‡
Total person days 3,724,768 2,053,185 1,671,583
Male gender 53.76 54.00 53.47
Age group
≤ 50 7.55 6.54 8.79
51–60 12.86 11.66 14.33
61–65 9.70 9.32 10.17
66–70 24.00 24.68 23.16
71–75 19.73 20.12 19.26
76–80 14.16 14.41 13.86
> 80 12.00 13.27 10.44
Race
Asian 4.49 4.29 4.73
Black 19.68 16.83 23.18
Hispanic 2.61 2.01 3.35
Other 1.87 1.78 1.98
Missing 4.89 4.26 5.67
White 66.46 70.83 61.09
Comorbidity
Hypertension 85.57 85.35 85.85
COPD 9.12 9.00 9.27
Renal disease 26.11 27.71 24.14
PVD 8.12 8.17 8.05
Hyperlipidemia* 79.56 80.53 78.38
‡ Characteristics of individuals that contributed at least 1 person day to that
column, and people could be represented in both columns, if they contributed
to both current and previous allopurinol use; *Hyperlipidemia was defined as
statin use or an ICD-9-CM code for hypercholesterolemia









PD (per 100 PY)
Current 2,053,185 person
days (5621.3 person years)
158 7.70 (2.81 per
100 PY)
Previous 1,671,583 person
days (4576.5 person years)
151 9.03 (3.30 per
100 PY)
PD person-days; PY person years
aFor MI, the person days with baseline 410, 412, 430–438, 428.xx and 429.2X
were removed. Also, the person days were censored at the occurrence of first
MI or an outpatient diagnosis of 410.X1 or inpatient or outpatient diagnosis of
410 except 410.x1 and 412
bFor stroke, the person days with baseline 410, 412, 430–438, 428.xx and 429.2X
were removed. Also, the person days were censored at the occurrence of first
stroke or an outpatient diagnosis of stroke or inpatient or outpatient diagnosis of
430–438 except for the dx codes for stroke. Stroke (430.xx, 431.xx, 433.x1 (433.01,
433.11, 433.21, 433.31, 433.81, 433.91), 434.xx excluding 434.x0 (434.01, 434.11,
434.91), 436.xx
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Discussion
In this study, we found that current use of allopurinol
was associated with a statistically significant and clinic-
ally meaningful reduction of the risk of acute cardio-
vascular events (incident stroke or MI) in patients
with gout and diabetes. We also provided crude inci-
dent rates for acute cardiovascular events in patients
with gout and diabetes, by current versus prior allo-
purinol use. Several findings in this study deserve fur-
ther discussion.
Our finding of 33% hazard reduction of incident stroke
or MI with current allopurinol use compared to prior
allopurinol use in patients with gout and diabetes is
novel. We are unaware of other large studies that have
examined this question. We chose to study this patient
population (gout and diabetes) due to a higher risk of
cardiovascular events. The beneficial cardiovascular effect
of allopurinol may be related to several potential mecha-
nisms including: (1) allopurinol associated attenuation of
intercellular adhesion molecule-1 levels noted in patients
after a recent stroke [27]; (2) improvement in endothelial
function and reduction of oxidative stress with allopurinol
[28–33]; and (3) reduction in glycosylated hemoglobin
(HbA1C) with high-doses of allopurinol [33]. The poten-
tial mechanisms of cardiovascular risk reduction with re-
duction of serum urate, including oxidative stress and
inflammation, were recently reviewed [34]. The hazards
were decreased by 29% in the prevalent user analyses. This
is consistent with a greater risk reduction seen in the inci-
dent user vs. prevalent user design, and might explain the
lack of finding an association if prevalent user design is
used and the sample size is smaller or events fewer.
Table 3 Unadjusted and age-adjusted association of current allopurinol use with Incident acute cardiovascular event composite
(MI or stroke) among patients with diabetes and gout
Unadjusted Age-adjusted
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Allopurinol user
Current 0.71 (0.56, 0.89) 0.003 0.67 (0.53, 0.85) 0.0007
Previous Ref Ref
Male Gender 0.85 (0.68, 1.06) 0.14 1.01 (0.80, 1.27) 0.95
Age
≤ 50 0.40 (0.17, 0.92) 0.03 - -
51-60 0.86 (0.49, 1.50) 0.59 - -
66-70 0.88 (0.54, 1.45) 0.62 - -
71-75 1.64 (1.03, 2.61) 0.04 - -
76-80 1.58 (0.97, 2.59) 0.07 - -
> 80 2.70 (1.70, 4.30) <0.0001 - -
61-65 Ref - -
Race
Asian 1.05 (0.62, 1.78) 0.85 0.95 (0.56, 1.60) 0.84
Black 0.90 (0.67, 1.21) 0.50 1.03 (0.77, 1.39) 0.84
Hispanic 1.35 (0.73, 2.47) 0.34 1.54 (0.84, 2.82) 0.16
Other 1.53 (0.79, 2.98) 0.21 1.59 (0.82, 3.10) 0.17
Missing 0.58 (0.30, 1.13) 0.11 0.73 (0.37, 1.43) 0.36
White Ref Ref
Comorbidity
Hypertension 1.08 (0.78, 1.50) 0.63 1.01 (0.73, 1.41) 0.93
Hyperlipidemia 0.90 (0.69, 1.17) 0.43 0.91 (0.69, 1.19) 0.49
COPD 1.10 (0.76, 1.59) 0.63 1.09 (0.75, 1.58) 0.66
Renal disease 1.40 (1.11, 1.78) 0.005 1.34 (1.06, 1.70) 0.02
Peripheral vascular disease 1.08 (0.73, 1.60) 0.70 0.96 (0.65, 1.43) 0.86
Immune diseases 1.05 (0.80, 1.39) 0.71 1.07 (0.81, 1.41) 0.62
Colchicine use 0.74 (0.51, 1.09) 0.13 0.77 (0.53, 1.12) 0.18
Significant odds ratios are in bold
COPD chronic obstructive pulmonary disease
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Our findings must be interpreted in the context of
current knowledge in this area. Most previous studies
examined stroke as part of a composite cardiovascular
outcome that included multiple cardiovascular out-
comes, not just stroke and MI. In a 7-year follow-up of a
2-year RCT in patients with chronic kidney disease with
glomerular filtration rate of < 60 ml/min, adjusted for
race, sex and renal function, allopurinol use was associ-
ated with lower risk of 0.43 (95% CI, 0.21–0.88) of
cardiovascular events (including CAD, cerebrovascular
disease, heart failure and peripheral vascular disease)
[35]. In an observational study of 187 patients with
hypertensive nephropathy, allopurinol use was associated
with a reduced hazard of 0.34 (p = 0.04) for cardiovascu-
lar disease (CAD, heart failure and stroke) [36]. In a
study using Scottish database, allopurinol use was asso-
ciated with no difference in adjusted hazards of cardio-
vascular events (non-fatal myocardial infarction, non-
fatal stroke and cardiovascular mortality) compared to
non-users 1.10 (95% CI, 0.95–1.26) [14]. Differences in
the conditions included in the composite cardiovascular
outcome, study populations and study designs, likely ex-
plain the differences in findings.
The three key studies examining the risk of MI re-
ported that compared to non-use, allopurinol use was
associated with a 48% decrease [13] vs. a 25% increase
[14] vs. no significant change [12] in the risk of MI. The
studies were similar in that they all used clinical data-
bases, assessed non-fatal MI and controlled for several
cardiovascular risk factors. However, several differences
were evident. Two studies used prevalent-user design
[12, 14], which puts them at the risk of adjusting for the
mediating factors and missing early events. Thus, it was
not surprising that the two studies that used prevalent
design showed increased risk [14] or no difference in
risk [12], while the only new user design study showed
risk reduction for MI [13]. Our study, using a new user
design, also shows statistically significant benefits of allo-
purinol for risk reduction of acute cardiovascular events,
and these findings were confirmed in several sensitivity
Table 4 Multivariable-adjusted associations of allopurinol use
with incident composite outcome (MI and stroke)
Incident MI or stroke
Hazard ratio (95% CI) p-value
Allopurinol User
Current 0.67 (0.53, 0.84) 0.0006
Previous Ref
Gender
Male 1.00 (0.80, 1.26) 0.99
Female Ref
Age, in years
≤ 50 0.40 (0.17, 0.93) 0.03
51–60 0.85 (0.49, 1.49) 0.57
66–70 0.88 (0.54, 1.45) 0.61
71–75 1.64 (1.02, 2.62) 0.04
76–80 1.59 (0.97, 2.60) 0.07
> 80 2.70 (1.69, 4.34) <0.0001
61–65 Ref
Race
Asian 0.92 (0.54, 1.55) 0.74
Black 0.97 (0.72, 1.31) 0.84
Hispanic 1.41 (0.76, 2.59) 0.27
Other 1.55 (0.79, 3.03) 0.20
Missing 0.71 (0.36, 1.40) 0.32
White Ref
Comorbidity
Hypertension 0.96 (0.69, 1.35) 0.83
Hyperlipidemia 0.91 (0.69, 1.20) 0.51
COPD 1.07 (0.74, 1.55) 0.73
Renal disease 1.36 (1.07, 1.73) 0.01
PVD 0.93 (0.63, 1.39) 0.74
Significant odds ratios are in bold
PVD peripheral vascular disease, COPD chronic obstructive pulmonary disease
Table 5 Sensitivity analyses with inclusion of colchicine in the main model or with immune disease in the model
Main modela + colchicine Main modela + immune disease
Incident MI or stroke
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Allopurinol User
Current 0.68 (0.54, 0.85) 0.001 0.67 (0.53, 0.84) 0.0006
Previous Ref Ref
Immune disease – – 1.04 (0.78, 1.37) 0.81
Colchicine 0.80 (0.55, 1.18) 0.26 – –
Significant odds ratios are in bold
aMain model was run without immune disease and without colchicine and included gender, age, race, hypertension, hyperlipidemia, peripheral vascular disease COPD
and renal disease
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analyses, including an analysis of prevalent allopurinol
users (to allow comparability to the two previous stud-
ies). Our study is among the first to show allopurinol’s
protective effect on acute cardiovascular event, i.e., inci-
dent stroke or MI, in patients with gout and diabetes.
However, our study differs in one important aspect from
the previous cited studies, i.e., we focused on patients with
both gout and diabetes. These patients likely have a higher
risk of acute cardiovascular events than patients with only
one of the two risk factors. This likely enriched our popu-
lation for more acute cardiovascular events and likely
made our study adequately powered, as intended.
This finding has a practical implication for patients and
providers. For patients with both gout and diabetes, allo-
purinol has an added benefit of reduction of the risk of
acute MI or stroke. The risk reduction is not only statisti-
cally significant, but also clinically meaningful (33% reduc-
tion). Patients should be informed of this potentially
beneficial effect, when allopurinol is first prescribed. This
risk reduction may potentially be even greater in patients
with other cardiovascular disease risk factors.
Our study findings must be interpreted considering
several limitations. The diagnosis of acute cardiovascular
events, our study outcome, was based on the presence of
ICD-9-CM codes, which may lead to misclassification
bias. However, previous studies have shown the
these codes for cardiovascular outcomes were accurate
[24]. There is also evidence of a reasonable accuracy for
codes used for covariates i.e., cardiovascular risk factors
[23–25]. Serum urate levels were available for a small pro-
portion of patients and therefore, we could not examine
whether these associations were or were not mediated via
the reduction of serum urate levels. The database also did
not allow us to include other variables such as body mass
index, smoking, diet and exercise, over the counter aspirin
use, and family history of cardiovascular disease, import-
ant covariates/risk factors for MI and stroke. We had con-
sidered excluding patients with cancer, but decided to
include them in our study to improve the generalizability
of study findings. A very small proportion of patients on
allopurinol (<0.5%) are usually receiving short-term allo-
purinol for prophylaxis against tumor lysis syndrome,
since they are receiving chemotherapy [37]; we doubt that
this study limitation influenced our results significantly.
Examination of effect of allopurinol on other outcomes,
including renal failure, dialysis or death, or rare side ef-
fects such as allergic reactions, was beyond the scope of
current study. Future studies should examine these
outcomes.
The contribution of healthy adherer effect to the ob-
served allopurinol’s beneficial effect for these outcomes
can not be ruled out, since patients adherent to/using
allopurinol may have other healthy behaviors, such as
high adherence to other medications, healthier lifestyle,
preventive care etc., which may all reduce the risk of
stroke and MI. Whether these findings can be general-
ized to populations other than diabetes and gout is not
known, and further study is needed in this area. Reasons
for allopurinol discontinuation can be other than non-
adherence, such as allopurinol cessation due to severe
renal disease (which is not a contraindication for allo-
purinol use, since allopurinol can be used even in pa-
tients on severe kidney dysfunction and also dialysis),
suspected or confirmed allergic reactions (which are ex-
tremely rare), the concomitant/new use of azathioprine
for the rheumatic disease or organ transplantation
(which is uncommon/rare), or switching to febuxostat,
another xanthine oxidase inhibitor launched in 2009
(which would have likely decreased the observed differ-
ence, but likely did not have a major impact given the
use of febuxostat in <7% patients with gout) [38]. These
confounding biases would have likely reduced the differ-
ences, and likely made our current estimates conservative,
since most of these conditions would likely increase the
risk of MI and/or stroke in current allopurinol non-users.
Study strengths include a large sample size, the use of a
sample that allows findings to be generalizable to cohorts
with gout or diabetes in the U.S., the use of a new user de-
sign that reduces bias in observational studies [39–41],
the inclusion of multiple risk factors for MI/stroke, and
the robustness of estimates in sensitivity analyses.
Conclusions
In conclusion, in robust analyses of data from a repre-
sentative sample of Americans, we found that
current allopurinol use was independently associated
with a lower risk of incident stroke or MI in patients
with gout and diabetes. Our findings provide evidence
for a potential cardiovascular protective effect of allopur-
inol in patients with gout and diabetes, a group of pa-
tients at high risk for cardiovascular events. Future
studies need to explore the factors that mediate this pro-
tective effect, and examine what proportion of variability
in this protective effect is explained by serum urate re-
duction and/or anti-oxidant effect of allopurinol.
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